Anticancer Agent Shikonin Is an Incompetent Inducer of Cancer Drug Resistance

Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2

(2011) J Chen et al.   ONCOGENE

Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis

(2009) Weidong Han et al.   APOPTOSIS

Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply

(2009) Gilles A. Spoden et al.   EXPERIMENTAL CELL RESEARCH

Naturally-occurring shikonin analogues – A class of necroptotic inducers that circumvent cancer drug resistance

(2008) Yanyan Xuan et al.   CANCER LETTERS

Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation

(2008) Gilles A. Spoden et al.   INTERNATIONAL JOURNAL OF CANCER

Shikonin exerts antitumor activityviaproteasome inhibition and cell death inductionin vitroandin vivo

(2008) Huanjie Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?

(2008) Pascal Sève et al.   LANCET ONCOLOGY

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

(2008) Heather R. Christofk et al.   NATURE

Identification of RIP1 kinase as a specific cellular target of necrostatins

(2008) Alexei Degterev et al.   Nature Chemical Biology

Expansion and evolution of cell death programmes

(2008) Alexei Degterev et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Bypassing cancer drug resistance by activating multiple death pathways – A proposal from the study of circumventing cancer drug resistance by induction of necroptosis

(2007) Xun Hu et al.   CANCER LETTERS